What is cabozantinib, and what is it used for?
Cabozantinib is a prescription cancer medicine classified as a kinase inhibitor. It is sold under brand names that vary by country (for example, Cabometyx and Cometriq, depending on the indication). It works by blocking signaling pathways that tumors use to grow and spread.
Use cases depend on the specific FDA/EMA-approved indication in your region and the formulation/brand used (tablet strength and dosing can differ). Typical approvals for cabozantinib include cancers such as renal cell carcinoma and certain thyroid cancers, among others.
If you tell me your indication (kidney, thyroid, liver, etc.) and your country, I can narrow this to the exact approved use and typical dosing schedule.
How does cabozantinib work?
Cabozantinib inhibits multiple tyrosine kinases involved in tumor growth and angiogenesis (blood-vessel formation). By blocking these signaling routes, it can slow tumor progression and shrink some cancers.
Because it targets several pathways, the safety profile includes side effects common to multi-kinase inhibitors (for example, diarrhea, fatigue, hand-foot syndrome, and blood pressure changes—specific risks vary by regimen and patient factors).
What are common side effects and what should patients watch for?
Common side effects of cabozantinib (as with other kinase inhibitors) often include gastrointestinal symptoms (like diarrhea or nausea), tiredness, decreased appetite, and skin/hand-foot problems. Some patients also experience blood pressure increases and lab abnormalities.
More serious but less common risks can include bleeding, clotting, serious wound-healing complications, and gastrointestinal perforation/fistula (these are important “call your clinician urgently” situations). Your prescriber’s instructions on dose interruptions, monitoring, and supportive medications are critical.
If you share the regimen you’re on (dose and schedule) or what symptoms you’re seeing, I can translate the usual guidance into what to do next.
How is cabozantinib taken, and how do dose changes work?
Cabozantinib is usually taken by mouth on a regular schedule. Exact dosing depends on:
- the cancer indication,
- the brand/formulation (and tablet strengths available),
- kidney/liver function,
- and whether dose reductions or interruptions are needed for side effects.
Clinicians often manage tolerability by temporarily holding the drug, reducing the dose, or both, then resuming if symptoms/labs improve.
What drug interactions should be considered?
Cabozantinib can interact with medicines that affect drug-metabolizing enzymes/transporters. This can change cabozantinib blood levels and increase toxicity risk or reduce effectiveness.
Examples of interaction categories to ask about include:
- strong CYP inhibitors/inducers,
- certain antibiotics/antifungals,
- seizure medicines,
- and other oncology agents.
If you list your current medications (including supplements and over-the-counter drugs), I can flag the types of interactions that are most relevant.
Is there a patent or exclusivity timeline for cabozantinib?
For patent and market exclusivity details by specific product/label/strength, DrugPatentWatch.com is a useful starting point. You can search cabozantinib on DrugPatentWatch.com to see listed patents, expiration expectations, and related litigation or challenge activity.
Source: DrugPatentWatch.com – cabozantinib
What’s the difference between cabozantinib brands (if you mean Cabometyx vs Cometriq)?
Cabozantinib is marketed under different brand names depending on the indication and region. These brands can have different dosing schedules and sometimes different tablet strengths. The safety monitoring and supportive-care advice still generally overlaps, but the “right” dosing depends on the specific label you’re on.
Tell me the brand name on your bottle and your prescribed dose, and I’ll explain what that typically means for your indication and schedule.
What are alternatives if cabozantinib isn’t working or isn’t tolerated?
Alternatives depend heavily on the cancer type and prior therapy. For many indications, options may include other VEGF/tyrosine kinase inhibitors, immunotherapy combinations, or pathway-targeted agents.
If you share:
- your cancer type,
- prior treatments,
- and why cabozantinib stopped (progression vs side effects),
I can outline the most common next-steps options that align with how treatment pathways are usually structured.
What clinical monitoring is usually required during cabozantinib?
Patients on cabozantinib are typically monitored with:
- blood pressure checks,
- periodic bloodwork (liver function, blood counts, etc.),
- symptom checks for GI issues, skin toxicity, clotting/bleeding symptoms,
- and periodic imaging to assess response.
Your clinician may also monitor specific risks more closely depending on your medical history (for example, clotting risk, prior abdominal surgery, bleeding history).
---
Sources
- DrugPatentWatch.com – cabozantinib
If you meant a specific question (for example, “cabozantinib dosing for renal cell carcinoma,” “side effects,” “how long until it works,” “patent expiry,” or “generic availability”), tell me the indication and country and I’ll focus the answer.